Protective Prototype-Beta and Delta-Omicron Chimeric RBD-Dimer Vaccines against SARS-CoV-2

Researchers developed a chimeric receptor-binding domain (RBD)-dimer vaccine approach to adapt SARS-CoV-2 variants. Compared with its homotypic forms, the chimeric vaccine elicited broader sera neutralization of variants and conferred better protection in mice.